Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- “No Serious ADR” Found in MHLW’s Fixed-Point Observation for Byetta
March 27, 2012
- Council Approves 80 Development Requests from 2nd Round
March 27, 2012
- PMDA to Improve Review, Safety Standards to Become World-Class Regulatory Authority: Chief Executive Kondo
March 26, 2012
- Notification Calls for Revision of Package Inserts for Diabetes, MS Treatments
March 23, 2012
- Kawasaki’s Tonomachi District to Invite NIHS, Set to Become International Basis for R&D
March 23, 2012
- Eliminating Drug Lag Will Require Measures to Reduce “Application Lag”: Mr Akagawa of PFSB
March 22, 2012
- Council Meeting Considers Working Team to Explore Directions for Drug Distribution Improvement
March 21, 2012
- Pharmaceutical Industry Should be Fostered as “Core Industry Taxed Not Punished”: Mr Sengoku of DPJ
March 21, 2012
- CSIMC to Accelerate Discussions on Long-Listed Drugs, Cost-Benefit Assessments: Dr Suzuki of HIB
March 21, 2012
- Health Insurance Claims Services Releases 37 Additional Cases Based on “1980 Notice”
March 19, 2012
- Generics Not Listed in All Specifications to Be Delisted from April 1 with Some Exceptions
March 19, 2012
- MHLW Submits Application for Membership in PIC/S on March 9
March 19, 2012
- PMDA to Abolish Current Rule on Re-Employment of Its Former Employees
March 16, 2012
- Integration of Advanced Healthcare Service Systems “Not Related” to Compassionate Use System: Korosho
March 16, 2012
- Bill to Amend PAL Unlikely to Be Submitted in Current Diet Session Due to Time Constraints: Health Minister Komiyama
March 15, 2012
- Korosho Begins Discussions Toward Integrating Senshin-iryo, Kohdo-iryo Systems
March 15, 2012
- Dr Sakurai of PMDA Stresses Need for Japan’s Participation in PIC/S to Create Global Inspection System
March 14, 2012
- Dissolution of Gliclazide Tablets Attributed to Large Particle Size: Generic Drug Quality Study Group
March 13, 2012
- Convincing Data Needed to Perpetuate Premium for New Drug Development: Mr Yoshida of MED
March 13, 2012
- Gov’t Releases Some Documents Related to Draft Statement on Iressa Lawsuits
March 13, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…